This study examined the expression of fibroblast growth factor receptor 2 (FGFR 2) splice variants, IIIb and IIIc, in normal and malignant human oral keratinocytes and in normal oral fibroblasts by RT-PCR using both exon-specific primers and primers common to both FGFR 2 isoforms. 
This study examined the expression of fibroblast growth factor receptor 2 (FGFR 2) splice variants, IIIb and IIIc, in normal and malignant human oral keratinocytes and in normal oral fibroblasts by RT-PCR using both exon-specific primers and primers common to both FGFR 2 isoforms. The fibroblast growth factor (FGF*) family is composed of a series of heparin binding growth factors of which 12 members have been identified (1) (2) (3) (4) (5) . The proteins are structurally-related single chain polypeptides, which range in size from 20-30 kDa and which share an overall amino acid homology of 30-55% with conservation of two cysteine residues (6) (7) (8) (9) . The peptides bind specifically to fibroblast growth factor receptors (FGFR), which are tyrosine kinase receptors that share a common structural arrangement and which are the products of four distinct receptor genes (FGFR 1-4; 10). Alternative splicing of exons that encode the second half of immunoglobulin domain III of FGFR 1, FGFR 2 and FGFR 3 give rise to membrane-spanning proteins with different ligand binding affinities (10) . The specificity of ligand binding of FGFR 2 resides in the second half of the third immunoglobulin domain where two alternatively spliced exons, termed IIIb and IIIc, encode this region of the receptor protein (10; Figure 1 ). The keratinocyte growth factor (KGF) receptor is encoded by the IIIb splice variant of FGFR 2 and binds KGF (FGF-7) and FGF-1 (acidic-FGF) with equal high affinity. By contrast, the IIIc splice variant binds FGF-1 and FGF-2, but not KGF (11) . In general, FGFR 2 exon IIIb (KGFR) is expressed in epithelial cells (11) (12) (13) and exon IIIc is present in mesenchymal and endothelial cells (11, 13, 14) .
Evidence is accumulating that FGF receptors are closely involved in tumour development and progression (1), but their exact function is unclear. The expression of FGFR 2, for example, appears to be variable with both loss of expression and over-expression having been demonstrated in a variety of different tumours (14) (15) (16) (17) (18) (19) (20) (21) (22) . The situation has not been clarified with regard to the isoforms of FGFR 2 because exon IIIb can be expressed alone, exon IIIc can be expressed alone, or both exons can be independently co-expressed (15, 18) .
We have shown that the mitogenic response of a series of oral malignant keratinocyte cell lines to KGF broadly correlates with the degree of cellular differentiation: well-differentiated keratinocytes are stimulated more by KGF than their less differentiated counterparts (23) . These studies have been extended to show that loss of tumour cell differentiation leads to a loss of KGF-induced mitogenesis and increased stimulation by FGF-2 (unpublished observations). What is not known, however, is whether this variation in response of the malignant keratinocyte cell lines to members of the FGF family is related to the expression of specific FGFR 2 isoforms. The purpose of the present study, therefore, was to examine the expression of FGFR 2 mRNA using RT-PCR in human malignant oral keratinocyte cell lines and to compare the presence of FGFR 2 variants with normal oral keratinocytes and fibroblasts.
Normal human oral keratinocytes and fibroblasts were obtained from fresh tissues collected from patients undergoing routine surgical procedures. Malignant cell lines and normal oral keratinocytes and fibroblasts were cultured as described previously and have been characterized with regard to differentiation and response to KGF (23,24; Table I ). Mitomycin Ctreated 3T3 fibroblasts (European Collection of Animal Cell Cultures, UK) were used in cultures of the normal oral keratinocytes in order to assist the growth of the primary keratinocytes and to limit host fibroblast contamination (25) . Primers specific for the exon splice variants of the 3rd immunoglobulin domain of FGFR 2 were designed according to the published sequence (26,27; Figure 1 ). Total RNA was prepared using the RNeasy total RNA kit (Qiagen, UK) and first strand cDNA was synthesized from 5 µg total RNA using the SuperScript pre-amplification system (Gibco). The cDNA was amplified using 30-40 PCR cycles using a standard PCR protocol. PCR amplification was repeated with all primer combinations on at least three occasions using different RNA samples.
All The results of this study demonstrate that normal keratinocytes express exons IIIb and IIIc of FGFR 2 whereas only exon IIIc was expressed in fibroblasts. The data confirm the target cell specificity of KGF which binds to FGFR 2/IIIb and stimulates epithelial cells but has no effect on fibroblasts because of the lack of expression of FGFR 2/IIIb in this cell type (11) (12) (13) . Somewhat surprisingly, the normal keratinocytes expressed exon IIIc of FGFR 2, a receptor isoform that gives rise to the bek variant of FGFR 2 and which is associated traditionally with the mesenchymal rather than the epithelial phenotype (11, 13, 14) . It is possible that the amplification of exon IIIc in the normal keratinocytes was because of 3T3 or host fibroblast contamination and, whilst the fibroblasts were removed from the cultures of normal keratinocytes prior to RNA preparation, trace amounts may have remained. Interestingly, expression of FGFR 2/IIIc has also been found in normal epithelial cells from the cornea, breast and endometrium, but the possibility of fibroblast contamination in these studies was not eliminated (14, 18, 28, 29) .
In a similar way to the normal keratinocytes, the malignant cell lines in this study also expressed both the IIIb and IIIc splice variant of FGFR 2. These cells were cultured in the absence of 3T3 fibroblasts from passage 3/4 and were used at passage~25, which suggests that fibroblast contamination in these cultures was extremely unlikely. The expression of FGFR 2/IIIc in human malignant epithelial tumour cells is not unprecedented (14, 15, 18, 30) and, invariably, exon IIIc is coexpressed with exon IIIb. In a minority of cell lines from the oral cavity, cervix, lung and endometrium, however, the expression of exon IIIc occurs in isolation (14, 15, 18, 30) . Taken together, the results suggest that the expression of FGFR 2/ IIIc may be more ubiquitous than was once thought, although it remains a possibility that the expression of both splice variants in keratinocytes occurs as a result of in vitro culture. Studies are in progress to examine whether the expression of the IIIc splice variant of FGFR 2 occurs in vivo and/or that exon IIIc expression is a specific characteristic of the malignant epithelial phenotype.
In the present study, well-differentiated keratinocytes (H357 and H413) expressed proportionally more FGFR 2/IIIb than IIIc, whereas the poorly differentiated cells (H314) expressed more FGFR 2/IIIc than IIIb. Variable expression of FGFR 2/ IIIb and IIIc in head and neck carcinoma cell lines has been reported previously (22) but the significance remains unknown. Interestingly, a low level of FGFR 2/IIIb has been shown to be associated with a significantly poorer prognosis in transitional cell bladder carcinoma (21) and this possibly corresponds to the known lack of differentiation in H314 of the present study. The results are consistent with previous observations in which the response of the cell lines to KGF (23) and FGF-2 (unpublished observations) have been examined. Well-differentiated keratinocytes, for example, are stimulated more by KGF than FGF-2 and undifferentiated cells show an increase in FGF-2-induced thymidine incorporation compared with that induced by KGF.
In rodent tumours, there is a strong correlation between the expression of the different FGFR 2 exons and the degree of tumour cell differentiation. In these tumours, undifferentiated cells exclusively express FGFR 2 IIIc, which results in stromal independence, activation of genes encoding FGF-2, FGF-3, FGF-5 and FGFR 1 and the formation of multiple potential autocrine loops (31) (32) (33) . The expression of FGFR 2 exon IIIb or IIIc is thought to arise by a mutually exclusive alternative splicing mechanism (11, 34) . All of the clonal cell populations in the present study, however, expressed both exons IIIb and IIIc. The results demonstrate that exon switching associated with the loss of cellular differentiation in human keratinocyte cell lines is not necessarily mutually exclusive.
When cDNA from normal and tumour-derived keratinocytes, but not fibroblasts, was amplified with primers flanking IIIb/ IIIc, an additional PCR product was detected. This amplification product was sequenced and found to contain both the IIIb and IIIc splice variants of FGFR 2 joined by an additional base pair and with the intronic sequence between the exons removed. Interestingly, the cDNA that contained both exons could not be amplified using primer 6 with either primers 1 or 2, which suggests that either some sequences downstream of exon IIIc have been deleted or that the truncated receptor is encoded by a separate gene. The co-expression of exons IIIb and IIIc joined in this manner has been detected previously in normal and hyperplastic prostate epithelium and normal and malignant breast epithelium (27,28). The receptor expressed by breast epithelial cells also contained an additional base pair between the two exons and it was predicted that because of the frame shift caused by this additional base pair, the translated product would terminate at base pair 13 in the IIIc exon (28) . This truncation would be predicted to produce a soluble protein with the ligand binding specificity of the KGF receptor (28) . It is unknown at present whether this truncated receptor is secreted by keratinocytes and, if it is secreted, what its function might be. Other truncated soluble FGF receptors have been described (10, 35) and it may be that these growth factors act to regulate the availability of the ligand to the cell.
In conclusion, the results of this study demonstrate that FGFR 2/IIIb and IIIc are co-expressed in malignant human oral keratinocyte cell lines. With a loss of tumour cell differentiation, there appears to be a partial switch from the expression of FGFR2/IIIb to IIIc, and we suggest that this confers a selective growth advantage to the poorly differentiated cells by becoming more susceptible to the growth stimulatory effects of FGF 2.
